EGFR A763_Y764insFQEA
|
Lung Cancer
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
gefitinib Sensitive: C3 – Early Trials
|
gefitinib Sensitive: C3 – Early Trials
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
osimertinib Sensitive: C3 – Early Trials
|
osimertinib Sensitive: C3 – Early Trials
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
EGFR A763_Y764insFQEA
|
Lung Cancer
|
erlotinib Sensitive: C3 – Early Trials
|
erlotinib Sensitive: C3 – Early Trials
|
EGFR A763_Y764insFQEA
|
NSCLC
|
EGFR A763_Y764insFQEA
|
NSCLC
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|
EGFR A763_Y764insFQEA
|
NSCLC
|
EGFR A763_Y764insFQEA
|
NSCLC
|
Tyrosine kinase inhibitor Sensitive: C4 – Case Studies
|
Tyrosine kinase inhibitor Sensitive: C4 – Case Studies
|
EGFR A763_Y764insFQEA
|
LUAD
|
EGFR A763_Y764insFQEA
|
LUAD
|
osimertinib Sensitive: D – Preclinical
|
osimertinib Sensitive: D – Preclinical
|
EGFR A763_Y764insFQEA
|
LUAD
|
EGFR A763_Y764insFQEA
|
LUAD
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
EGFR A763_Y764insFQEA
|
LUAD
|
EGFR A763_Y764insFQEA
|
LUAD
|
erlotinib Sensitive: D – Preclinical
|
erlotinib Sensitive: D – Preclinical
|
EGFR A763_Y764insFQEA
|
NSCLC
|
EGFR A763_Y764insFQEA
|
NSCLC
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
EGFR A763_Y764insFQEA
|
NSCLC
|
EGFR A763_Y764insFQEA
|
NSCLC
|
dacomitinib Sensitive: D – Preclinical
|
dacomitinib Sensitive: D – Preclinical
|
EGFR A763_Y764insFQEA
|
NSCLC
|
EGFR A763_Y764insFQEA
|
NSCLC
|
osimertinib Sensitive: D – Preclinical
|
osimertinib Sensitive: D – Preclinical
|